Abstract
To asthmatic patients with moderate to severe persistent asthma, two main treatment options are recommended: The combination of a long-acting inhaled β2-agonist with inhaled corticosteroids or the use of a higher dose of inhaled corticosteroids. The aim of this study was to evaluate which drug option is more favorable.
This study included 60 asthmatic patients uncontrolled on low doses of ICSs. They were randomized into two groups. Group (1): 30 patients received twice daily inhaled formetrol and budesonide in a dose of 12mcg and 400mcg, respectively. Group (2): 30 patients received two fold the previous dose of budesonide 800mcg/BID alone. A comparative study was carried out at Outpatient Chest Clinic of Fayoum Hospital University for a period of 24weeks using the spirometric data of patients of the two groups before and after treatment.
Results showed that the combination therapy of inhaled formetrol and budesonide is modestly more effective in the reduction of symptoms and in improving the lung functions than with a higher dose of budesonide alone.
Adding formetrol in a dose of 12μg plus budesonide in a dose 400μg b.i.d. is more favorable in treatment of asthma than a higher dose of budesonide (800μg b.i.d).